• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study.

作者信息

Torres Tiago, Yeung Jensen, Prajapati Vimal, Ribero Simone, Balato Anna, Valerio Marzano Angelo, Cruz Maria João, Paiva Lopes Maria João, Lazaridou Elizabeth, Carrascosa Jose-Manuel, Alvarenga José Miguel, Farinha Pedro, Duarte Bruno, Sood Siddhartha, Rankin Brian D, Ortoncelli Michela, Caccavale Stefano, Ferrucci Silvia Mariel, Rosa Gilberto Pires, Daponte Athina Ioanna, Silvi Gianmarco, Peris Ketty, Gori Niccolò, Herranz Pedro, Prignano Francesca, Kolios Antonio, Rompoti Natalia, Gkalpakiotis Spyridon, Chiricozzi Andrea

机构信息

Department of Dermatology, Centro Hospitalar Universitário de Santo António Porto, Porto, Portugal.

Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.

出版信息

J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e756-e761. doi: 10.1111/jdv.20581. Epub 2025 Feb 6.

DOI:10.1111/jdv.20581
PMID:39912554
Abstract
摘要

相似文献

1
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study.
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e756-e761. doi: 10.1111/jdv.20581. Epub 2025 Feb 6.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.度普利尤单抗、曲罗芦单抗和乌帕替尼在特应性皮炎患者中的真实世界有效性和安全性：一项为期52周的国际多中心回顾性队列研究。
Dermatol Ther (Heidelb). 2025 Aug;15(8):2295-2305. doi: 10.1007/s13555-025-01453-8. Epub 2025 Jun 3.
4
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.
Int J Dermatol. 2025 Aug 20. doi: 10.1111/ijd.70027.
5
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂（“Measure Up 1”和“Measure Up 2”研究）及度普利尤单抗（“Heads Up”研究）相比，乌帕替尼可快速改善瘙痒并清除皮肤症状：三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
6
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性：来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
7
Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?曲罗芦单抗在三级中心的真实世界临床经验：对于使用度普利尤单抗治疗结膜炎患者的另一种选择？
Dermatol Ther (Heidelb). 2025 Aug;15(8):2275-2279. doi: 10.1007/s13555-025-01446-7. Epub 2025 May 29.
8
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.乌帕替尼对比度普利尤单抗治疗成人中重度特应性皮炎的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023.
9
Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort.特应性皮炎的药物生存率及全身治疗结果的预测因素：来自瑞典全国队列的数据。
Acta Derm Venereol. 2025 Aug 7;105:adv43464. doi: 10.2340/actadv.v105.43464.
10
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.使用曲罗芦单抗治疗长达4年的头颈部特应性皮炎患者的长期疾病控制和最小疾病活动度
Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.

引用本文的文献

1
Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort.特应性皮炎的药物生存率及全身治疗结果的预测因素：来自瑞典全国队列的数据。
Acta Derm Venereol. 2025 Aug 7;105:adv43464. doi: 10.2340/actadv.v105.43464.